Edition:
United States

Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

106.90EUR
10:56am EDT
Change (% chg)

€0.00 (+0.00%)
Prev Close
€106.90
Open
€107.20
Day's High
€107.50
Day's Low
€106.75
Volume
682,735
Avg. Vol
2,145,336
52-wk High
€112.00
52-wk Low
€83.45

Latest Key Developments (Source: Significant Developments)

Crispr and Casebia announce commercial license agreement with Maxcyte
Tuesday, 14 Mar 2017 07:00am EDT 

Crispr Therapeutics Ag : Crispr Therapeutics and Casebia Therapeutics announce commercial license agreement with Maxcyte . Maxcyte will supply systems Co and Casebia as part of license agreement and will receive upfront, milestone, and sales-based payments . Says commercial license builds on an existing research and clinical licensing agreement for select disease areas .Crispr, Casebia will obtain non-exclusive commercial-use rights to Maxcyte's cell engineering platform to develop crispr/CAS9-based therapies for SCID.  Full Article

Bayer places Covestro shares at 66.50 euros apiece
Wednesday, 1 Mar 2017 02:05am EST 

Bayer : Says has reduced its holding in Covestro from 64.2 percent to 53.3 percent . Says Places Covestro shares at 66.50 euros apiece . Says still expects a mid-single-digit percentage increase in core earnings per share from continuing operations in 2017 . Says Covestro will continue to be fully consolidated in Bayer’s statement of financial position .  Full Article

FTC approves final order settling charges for Boehringer Ingelheim’s asset swap with Sanofi
Friday, 24 Feb 2017 01:47pm EST 

U.S. Federal Trade Commission (FTC) :U.S. FTC - Approved final order settling charges that Boehringer Ingelheim’s $13.53 billion asset swap with Sanofi would likely be anticompetitive.  Full Article

Dow Chemical updates on patent dispute with Bayer
Thursday, 9 Feb 2017 09:38am EST 

Dow Chemical Co : Dow Chemical - In January 2017, the USPTO issued final office actions for two of the patents asserted in a case, including the ‘962 patent . Dow Chemical - USPTO rejected all relevant claims related to a patents dispute with Bayer, based on the doctrine against double-patenting . Dow Chemical - Re-examination proceedings with respect to other two patents remain pending, although co anticipates that USPTO will likewise invalidate those patents . Dow Chemical - Although Bayer may appeal these decisions, co believes USPTO final office actions will provide a strong basis to vacate the arbitral award .Dow Chemical - As part of the co’s review of the arbitral award, co assessed the legal and factual circumstances of the case.  Full Article

Regeneron says price increases unrelated from innovation will be pushed back on
Thursday, 9 Feb 2017 09:00am EST 

Regeneron Pharmaceuticals Inc - : Regeneron CEO: "As we further diversify our product related revenue stream, we do not plan to provide eylea guidance after 2017" . Regeneron CEO says Amgen's asserted patent claims on repatha are invalid and we look forward to pursuing our appeal over the coming months: conf call . Regeneron's Bob Terifay says Eylea will continue for co over the years to come . Regeneron: Eylea sales growth has slowed reflecting normal market dynamics for the product that has been around for over 5 yrs with no price hike since launch . Regeneron CEO says changes in pharmaceutical drug pricing will need congressional action . Regeneron CEO "Price increases that are unrelated or uncoupled from innovation will be pushed back on" . Regeneron CEO: Constant price increases & magnitude of them are reflection of tone deafness on those taking hikes & complexities about how rebates work . Regeneron CEO: "There is an opportunity to come up with more responsible pricing", in relation to rheumatoid arthritis drug, sarilumab . Regeneron CEO: "Pharma is running around saying the middleman (PBM) is taking too much; the middleman says prices are too high and patients are wondering what is really going on" . Regeneron CEO: "price increases are nice but if you cannot get them you better be able to innovate and that is our sweet spot" Further company coverage: [AMGN.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Bayer says Regorafenib granted priority review in Japan
Friday, 20 Jan 2017 02:02am EST 

Bayer AG : Bayer says Regorafenib from Bayer granted priority review in Japan for the second-line treatment of liver cancer Further company coverage: [BAYGn.DE] ((frankfurt.newsroom@thomsonreuters.com; +49 69 7565 1270;)).  Full Article

Bayer, Leica Biosystems to develop companion diagnostic test for cancer patients
Wednesday, 21 Dec 2016 02:38am EST 

Bayer AG : Says develops companion diagnostic test for cancer patients together with Leica Biosystems . The partners will use Leica Biosystems expertise in assay development, regulatory approval and commercialization of companion diagnostic tests .Financial terms of the agreement were not disclosed.  Full Article

Bayer announces FDA acceptance of supplemental biologics license application for Mybetaapp and Betaconnect navigator
Wednesday, 14 Dec 2016 12:18pm EST 

Bayer:Bayer announces fda acceptance of supplemental biologics license application for mybetaapp and betaconnect navigator.  Full Article

Bayer buys U.S. animal health products from Boehringer
Wednesday, 7 Dec 2016 11:05am EST 

Bayer AG : Says Boehringer Ingelheim Vetmedica, Inc. and Bayer enter into agreement for purchase of U.S. Cydectin® product portfolio . Says to acquire Boehringer's Cydectin bovine and ovine endectocide products in United States .Says the sale of Boehringer's U.S. Cydectin products is a required step toward its acquisition of Merial as part of a swap transaction with Sanofi.  Full Article

Monsanto provides update on Bayer merger
Tuesday, 22 Nov 2016 06:04am EST 

Bayer Ag : Monsanto co - in connection with merger with Bayer, a purported class action lawsuit, captioned ken gawrych, was filed on nov. 16, 2016 . Monsanto- complaint asserts board breached fiduciary duties by agreeing to deal not adequately reflecting co's true value to obtain personal benefits .Monsanto- complaint seeks to enjoin the consummation of the merger; monsanto believes the claims asserted in lawsuit are without merit.  Full Article

More From Around the Web

Photo

Monsanto meets its match as Hindu nationalists assert power in India

NEW DELHI Tens of millions of dollars were within reach for M. Prabhakara Rao as he prepared in April 2015 to take his Indian cotton seed company public.